Antihistamine Recall: 34,000 Bottles at Highest Risk Level
The FDA assigned a rare Class I risk to allergy medication distributed nationwide for unusual cross-contamination with ranitidine.
It is not the first recall involving antihistamines, but this event represents one of the earliest instances classified under the highest possible alert status. The U.S. Food and Drug Administration (FDA) reserves its top risk level for situations in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death, according to definitions listed on FDA.gov. A report released Tuesday indicates that the affected antihistamine was manufactured by an India operation for JB Chemicals and Pharmaceuticals Ltd.
The product consists of 100-count bottles of five-milligram (5 mg) cetirizine hydrochloride tablets, a generic formulation similar to brands like Zyrtec. Although Zyrtec is not affected by this recall, the specific lot numbers impacted are GY825029, GY825030, GY825031, and GY825032. The expiration date marked on these labels was October 2028. The manufacturer voluntarily initiated a nationwide recall on June 24, with 34,200 bottles affected.
The Class I update follows FDA reporting that the issue triggering the event was cross-contamination with other products. Customer complaints regarding the appearance of discolored tablets and red dots observed on Cetirizine Hydrochloride Tablets USP 5 mg were determined to be caused by ranitidine contamination. Ranitidine is an important acid-reducing medication widely used to treat conditions including gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome.
Commonly known by the brand name Zantac, ranitidine was initially removed from the U.S. market in April 2020 due to the presence of an ingredient that the agency called a probable human carcinogen. However, a reformulated version was approved by the agency in November 2025 following extensive safety testing and manufacturing improvements. In either case, drug manufacturer quality control standards would not permit cross-contamination during production or packaging. This appears to be why the FDA has determined that the risk of drug interaction for users is significant.
This research note is provided for laboratory use only. It does not constitute medical advice, clinical guidance, or a recommendation for human consumption. All information regarding dosage, administration, and therapeutic application is strictly for scientific reference purposes.